Nyrada Inc Update on GLP Studies
Nyrada Inc. released an update on the Good Laboratory Practice (GLP) studies being conducted on the company’s drug candidate to… Read more
Nyrada GLP Studies Update
Highlights: •Two key safety studies have provided data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Nyrada remains on track for 2QFY2025 commencement of first in-human Phase I clinical trial for its Brain Injury drug candidate… Read more
Nyrada Signs Strategic Partnership with US Brain Injury Detection and Monitoring Company
Highlights: •Nyrada signs strategic partnership agreement with Rebion to advance brain injury therapies and outcomes. •Partnership will facilitate joint research… Read more
Nyrada Inc (ASX:NYR) Statistically Significant Neuroprotection Achieved in Nyrada’s Preclinical Brain Injury Study
Nyrada Inc. (ASX: NYR) have released results from an animal study of their lead Brain Injury program drug candidate NYR-BI03…. Read more
Nyrada Inc – Nyrada Half Year FY2024 Results
Highlights: •Brain Injury Program: -Stroke model study underway with drug well tolerated to date. Efficacy results imminent. -Walter Reed brain… Read more
Nyrada Inc Half – year Report
Nyrada Inc. Appendix 4D Half-year report
Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Brain Injury Program: -Stroke model study underway with drug well tolerated to date, efficacy results imminent. -Walter Reed brain… Read more
Nyrada Receives A$3.54M R&D Tax Incentive Rebate
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases… Read more